Publication: Intramuscular anti-D in chronic immune thrombocytopenia children with severe thrombocytopenia
Issued Date
2013-12-01
Resource Type
ISSN
1442200X
13288067
13288067
Other identifier(s)
2-s2.0-84890443282
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pediatrics International. Vol.55, No.6 (2013)
Suggested Citation
Nongnuch Sirachainan, Usanarat Anurathapan, Ampaiwan Chuansumrit, Duantida Songdej, Pakawan Wongwerawattanakoon, Sakara Hutspardol, Pimpun Kitpoka Intramuscular anti-D in chronic immune thrombocytopenia children with severe thrombocytopenia. Pediatrics International. Vol.55, No.6 (2013). doi:10.1111/ped.12179 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32059
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Intramuscular anti-D in chronic immune thrombocytopenia children with severe thrombocytopenia
Other Contributor(s)
Abstract
Nine patients with chronic immune thrombocytopenia and platelet counts <20 × 109/L, with a median age of 7.8 (3.8-15.5) years, received three phases of 10 mcg/kg/dose of intramuscular anti-D. Phase 1 was anti-D daily for 5 days, followed by phase 2, anti-D weekly for 12 weeks and withheld when platelet counts ≥20 × 109/L, and then phase 3 was anti-D once every 2 weeks for 24 weeks. According to the International Working Group criteria, in phase 1, 66.7% of patients responded to the treatment. In phases 2 and 3, 11.1% (0-41.7%) and 7.7% (0-33.3%) of total episodes of follow up, respectively, responded to the treatment. Therefore, intramuscular anti-D given at a dose of 10 mcg/kg for 5 days is an alternative method to raise platelet counts in chronic immune thrombocytopenia children with severe thrombocytopenia where the intravenous form of anti-D is not available. © 2013 Japan Pediatric Society.